CODX vs. TELA, MLSS, FONR, GUTS, MGRM, NTRB, EDAP, STIM, ICAD, and HYPR
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include TELA Bio (TELA), Milestone Scientific (MLSS), FONAR (FONR), Fractyl Health (GUTS), Monogram Orthopaedics (MGRM), Nutriband (NTRB), Edap Tms (EDAP), Neuronetics (STIM), iCAD (ICAD), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs.
Co-Diagnostics (NASDAQ:CODX) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
Co-Diagnostics has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 6.1% of Co-Diagnostics shares are owned by company insiders. Comparatively, 6.0% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
TELA Bio has a net margin of -60.49% compared to Co-Diagnostics' net margin of -563.93%. Co-Diagnostics' return on equity of -54.94% beat TELA Bio's return on equity.
Co-Diagnostics received 214 more outperform votes than TELA Bio when rated by MarketBeat users. However, 74.68% of users gave TELA Bio an outperform vote while only 62.90% of users gave Co-Diagnostics an outperform vote.
In the previous week, Co-Diagnostics had 2 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for Co-Diagnostics and 0 mentions for TELA Bio. Co-Diagnostics' average media sentiment score of 0.50 beat TELA Bio's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.
Co-Diagnostics currently has a consensus price target of $1.50, suggesting a potential upside of 107.76%. TELA Bio has a consensus price target of $9.25, suggesting a potential upside of 240.07%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts clearly believe TELA Bio is more favorable than Co-Diagnostics.
Summary
Co-Diagnostics beats TELA Bio on 10 of the 18 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 2/5/2025 by MarketBeat.com Staff
